Ailux is an AI-native biotech company headquartered in Shanghai and currently a wholly-owned subsidiary of XtalPi (2228.HK), a global leader in AI drug discovery. Established as an independent operation five years ago with its own dedicated team, platforms, and pipeline, Ailux combines proprietary AI biologics platforms with a 30,000 square foot wet lab to discover and engineer next-generation biologics across multiple therapeutic areas. The company’s global team of approximately 150 spans China, the UK, and the US, drawing on the distinct strengths of each geography. Ailux has collaborated with Eli Lilly, Johnson & Johnson, and UCB, and is now advancing its own pipeline with the first programs expected to enter clinical development by 2027.

Ailux

Org chart

Teams

Offices